In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the departments of ophthalmology and biomedical engineering, to play a pivotal ...

The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare eye disease called MacTel. This procedure offers hope to patients like ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...

UniQure's therapy, called AMT-130, reduced disease progression by 75% at 36 months in patients who received a high dose.

However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...